Relapse of acute myelogenous leukemia has been associated with clonal cytogenetic evolution, but no study focused specifically on relapse after allogeneic hematopoietic stem cell transplantation (HSCT). We compared karyotypes in 160 patients at both diagnosis and relapse either after allo-HSCT (n 5 26) or standard chemotherapy (n 5 134) using chromosome banding analysis combined with fluorescein in situ hybridization. There were 71 females and 89 males (19.7-80.6 years). At diagnosis, aberrant karyotypes were more frequent in the HSCT than in the chemotherapy cohort (16 of 26; 61.5% versus 63 of 134; 47.0%). This was most obvious in patients with unfavorable cytogenetics (8 of 26; 30.8% versus 19 of 134; 14.2%; P 5 .032). Differences in the karyotypes between diagnosis and relapse were more frequent in the allo-cohort (14 of 26; 53.8% versus 49 of 134; 36.6%) than in the conventional cohort (n.s.), mainly because of newly emerging cytogenetic alterations. Appearance of $3 new clonal alterations was more frequent in the allocohort (6 of 12; 50.0% with clonal evolution versus 5 of 41; 12.2%, P 5.005). The mean number of cytogenetic alterations per patient was increasing from 2.0 at diagnosis to 4.0 at relapse in the allo-cohort, in the conventionally treated patients from 0.9 to 1.3 (both P \.001). Thus, higher frequencies of clonal evolution and increasing cytogenetic complexity were observed in the stem cell recipients probably related to the more unfavorable cytogenetic profiles already depicted at diagnosis.
INTRODUCTION
In acute myelogenous leukemia (AML), the strongest antileukemic effect is provided by allogeneic hematopoietic stem cell transplantation (HSCT). However, considering the risks of allogeneic HSCT and the heterogeneity of AML from clinical as well as from genetic aspects [1, 2] , recent studies aim to select patients with high-risk profiles for allogeneic HSCT, whereas those with less adverse risk patterns receive standard chemotherapy [3] [4] [5] . The overrepresentation of patients with adverse risk profiles in the transplant setting is associated with high posttransplant relapse rates between 30% and 50% depending on the different subentities, the history of AML (de novo versus secondary), or other parameters such as the remission status before HSCT. Reduced-intensity conditioning (RIC) regimens, which allowed the inclusion of elderly patients or patients with comorbidities [6] , have less of an antileukemic effect and thus are followed by higher relapse rates as well.
Relapse of AML has previously been associated with cytogenetic clonal evolution in nearly 40% of patients when chromosome banding was performed [7] . Raghavan et al. [8] compared 27 paired diagnostic and relapsed AML samples with single nucleotide polymorphism (SNP) genotyping arrays. Newly acquired segmental uniparental disomies (UPDs) were observed at relapse in 11 AML samples (40%), frequently including 13q where the FLT3 gene is localized. Thus, acquisition of a segmental UPD was shown to be a common event associated with relapse of the AML. In acute lymphoblastic leukemia (ALL), Kawamata et al. [9] performed SNP-chip analysis in 14 pediatric patients at diagnosis, remission, and relapse. With this highly sensitive method, all 14 cases had genomic alterations at relapse, and additional genomic abnormalities not present at diagnosis were detected in 71% of cases. On the other hand, they detected disappearance as well of genomic alterations, especially deletions.
So far to our knowledge, only 1 study focused on the cytogenetic evolution patterns in patients at relapse of acute leukemias (AML and ALL) specifically after allogeneic HSCT, but performed no direct comparison with the situation after conventional therapy [10] . Here, we performed comparisons of the cytogenetic patterns in 160 patients at relapse and at diagnosis of AML after allogeneic HSCT (n 5 26) or after standard treatment (n 5 134) using chromosome banding analysis and fluorescein in situ hybridization (FISH).
PATIENTS AND METHODS

Patients
This retrospective analysis was based on a total of 160 patients (71 females, 89 males; median age, 62.6 years; range: 19.7-80.6 years) who developed relapse of AML after allogeneic HSCT (n 5 26) or conventional treatment (n 5 134). The basis for inclusion of patients in the study was the availability of cytogenetic results at both diagnosis and relapse, respectively, investigated in our laboratory. One hundred thirty-four patients had de novo AML, 12 had secondary AML after myelodysplastic syndrome (s-AML), and 13 had therapy associated AML (t-AML) (history of AML was missing in 1 case) ( Table 1 ). In the HSCT cohort, 11 patients each had received myeloablative (MA) conditioning and RIC, respectively (data on conditioning regimens was not available in 4 stem cell recipients). Bone marrow (BM) samples were sent between August 2005 and June 2009 from different hematologic centers and clinics to the MLL Munich Leukemia Laboratory for diagnostic workup. Patients agreed with the use of laboratory data for research studies when they gave written consent to the performance of genetic analysis of BM samples. The study was performed in accordance with the declaration of Helsinki.
Parameters Assessed
Cytomorphology
Morphologic classification of AML cases was performed according to the FAB system [11, 12] .
Cytogenetics
Chromosome banding technique and FISH were performed according to standard methods [13] . Following the WHO classification of 2008, cases were categorized in the following cytogenetic subgroups: t(15;17)(q22;q12), t(8;21)(q22;q22), inv(16)/t(16;16) (p13;q22), normal karyotype, trisomy 8 (18) as sole abnormality or in combination with other aberrations, deletions of 5q, 9q, and 20q, t(6;9)(p23;q34), t(3;21) (q26;q22), inv(3)/t(3;3)(q21;q26), complex aberrations ($3 clonal cytogenetic abnormalities), 11q23/MLL rearrangements, numeric gains of chromosomes 4, 11, or 21, other trisomies, other unbalanced and balanced alterations, and alterations that did not correspond to either of the mentioned groups (''others''). The prognostic categorization of karyotypes was performed according to revised MRC criteria [14] . Further, we documented the numbers of cytogenetic alterations, both at diagnosis and relapse of AML. The numbers of numeric gains, losses, unbalanced structural, and balanced rearrangements were recorded both at diagnosis and relapse. Only patients, in whom results of chromosome banding analysis were available at diagnosis and at relapse from our our own laboratory, were included in the study.
To analyze the presence of clonal evolution and to characterize its patterns, we first documented differences in cytogenetics between diagnosis and relapse in each patient. Second, patients with cytogenetic differences were categorized whether they showed cytogenetic evolution (ie, acquisition of new cytogenetic alterations), or clonal cytogenetic regression (ie, loss of previously detectable cytogenetic alterations). The combination of clonal evolution and clonal regression was documented as well. The types of additional cytogenetic changes were characterized as follows: balanced rearrangements, unbalanced aberrations, or complex alterations (when patients developed at least 3 new chromosomal alterations). The appearance of a new independent clone was separately documented.
Statistics
For comparison of dichotomous variables between the different groups, the 2-sided Fisher's exact test was used. Differences in the distributions of prognostic factors in subgroups were analyzed by chi-square, Fisher's exact test, and by Wilcoxon test. Survival was defined as the time from diagnosis to death or date of the last follow-up. All tests were 2-sided, accepting P # .05 as indicating a statistically significant difference. Statistical analysis was performed with the SPSS software (version 14.0; SPSS, Chicago, IL).
RESULTS
In the 26 stem cell recipients, recurrence of disease was diagnosed with a median interval of 276 days posttransplant (range: 71-683 days). In the conventionally treated cohort consisting of 134 patients, 121 patients were included in the study at first relapse with a median interval of 320 days (range: 73-1259 days from standard treatment from day 1), and 13 patients at the second relapse with a median interval of 555 days from diagnosis (range: 103-966 days) as cytogenetic results were available from this time point only.
Cytomorphology and Cytogenetics at Diagnosis of Disease Table 1 shows the distribution of FAB subtypes, the cytogenetic categories, and the subdivision of cytogenetic cases according to the different prognostic subgroups following the revised MRC criteria [14] . Cytogenetic aberrations at diagnosis were more frequent in the allogeneic HSCT group (16 of 26; 61.5%) than in the control cohort (63 of 134; 47.0%) (n.s.). In the cohort of the conventionally treated patients, a total of 17 of 134 (12.7%) had favorable karyotypes in comparison to no patient in the cohort of the allo-transplanted patients (n 5 0 of 26). 
Comparison of Cytogenetic Patterns at Diagnosis and at Relapse
Aberrant karyotypes at diagnosis and relapse First, we compared the frequencies of aberrant karyotypes at diagnosis and relapse in both cohorts (Table  2A and Figure 1A ). At diagnosis, aberrant karyotypes were more frequent in the allogeneic HSCT group (16 of 26; 61.5%) than in the conventionally treated cohort (63 of 134; 47.0%; n.s.). At relapse, because of cytogenetic clonal evolution, aberrant karyotypes showed an increase in both cohorts but were still significantly more frequent in the HSCT cohort (20 of 26; 76.9%) than in the conventionally treated patients (73 of 134; 54.5%; P 5 .049). (Cytogenetic changes from diagnosis to relapse are explained below in more detail.)
At diagnosis there was a higher frequency of unfavorable karyotypes in the HSCT cohort (8 of 26; 30.8%) in comparison with 19 of 134 (14.2%) in the conventionally treated cohort (P 5 .032).
Clonal cytogenetic changes from diagnosis to relapse
Differences in the cytogenetic patterns between diagnosis and relapse were more frequent in the allogeneic HSCT cohort (Figure 2A-D the HSCT cohort, 14 of 26 (53.8%) were observed with changes in karyotypes, but only 49 of 134 (36.6%) of the conventionally treated patients (n.s.). The differences of clonal alterations in both cohorts were mostly because of the appearance of new cytogenetic alterations at relapse (''clonal cytogenetic evolution''). Again, acquisition of new cytogenetic alterations was more frequently observed in the HSCT cohort when compared to the conventionally treated patients (12 of 26; 46.2%; versus 41 of 134; 30.6%). These differences between both cohorts, however, did not reach statistical significance, probably because of the limited number of patients in the HSCT cohort. Focusing on the HSCT cohort, cytogenetic changes at relapse were more frequent in the cohort of the RIC patients (8 of 11; 72.7%) when compared to the Figure 1. (A) Frequency of aberrant karyotypes (KTs) and of clonal evolution at diagnosis and at relapse of AML. The recipients of allogeneic HSCT (allo-HSCT; n 5 26) and patients with conventional treatment were compared (conv.; n 5 134). The symbol * above the columns indicates that the frequency showed statistically significant differences between diagnosis and relapse (see as well Table 2b ). (B) Mean numbers of cytogenetic alterations per patient at diagnosis and at relapse of AML in the recipients of allogeneic HSCT (allo-HSCT; n 5 26) and in the conventionally treated cohort (conv.; n 5 134).
MA conditioned patients (5 of 11; 45.5%; n.s.) Acquisition of new cytogenetic changes was observed in 7 of 11 patients from the RIC cohort (63.6%), and in 4 of 11 MA conditioned patients (36.4%) (n.s.). (Data on conditioning strategies were missing in 4 patients). In addition, we performed univariate analysis, taking age, interval of relapse from HSCT, history of AML (de novo versus secondary), and the occurrence of chromosomal changes at relapse on subsequent survival outcomes in the HSCT cohort into account. We observed no significant influences of these parameters. This, however, might have been because of the limited size of the HSCT cohort.
Loss of a cytogenetic clonal alteration (''clonal regression'') was similarly distributed in both cohorts (allogeneic HSCT: 3 of 26; 11.5%; conventional treatment: 17 of 134; 12.7%). Clonal regression was frequently represented by loss of a trisomy 8 (HSCT cohort: n 5 1; conventional cohort: n 5 5) ( Figures  2D and 3D) . One patient from the HSCT group (3.8%) and 8 patients from the conventional cohort (6.0%) showed appearance of new cytogenetic alterations and loss of other alterations in parallel (n.s.).
Characterization of the new cytogenetic alterations at relapse
The types of new genetic alterations differed between the allo-cohort and the conventionally treated patients significantly (Table 2a) : patients from the HSCT cohort developed new complex aberrationsbeing defined by the appearance of $3 clonal cytogenetic alterations-in 6 of those 12 cases (50.0%) with the phenomenon of clonal cytogenetic evolution, whereas in the conventionally treated cohort, complex In the HSCT cohort, clonal evolution at relapse of AML was frequently represented by structural losses of 5q or 9q, or structural gains of 15q. In the standard treatment cohort, clonal evolution was most frequently being represented by trisomy 8 or structural gains of 11q or 17q (Figures 2C and 3C) . Clonal regression showed clustering with regard to trisomy 8 or structural losses of 11p in the standard treatment cohort (in the HSCT cohort, only 3 patients showed clonal regression at relapse) ( Figures 2D and 3D ).
Finally, we analyzed the frequency of clonal cytogenetic evolution in the larger cytogenetic subgroups (normal karyotype, 18, and complex aberrant karyotypes) in the total cohort. In the patients with a normal karyotype, 21 of 81 (25.9%) showed clonal cytogenetic evolution. This was only slightly less frequent when compared to the subgroups with trisomy 8 (3 of 8; 37.5%), or with complex aberrant karyotypes (5 of 13; 38.5%). When both cohorts were investigated separately (allo-HSCT versus conventional treatment), 4 of 10 stem cell recipients (40.0%) with normal karyotypes at the first manifestation of AML showed clonal cytogenetic evolution at posttransplant relapse, which was similar to the conventional cohort (17 of 71; 23.9%). No stem cell recipient with a 18 (n 5 2) developed clonal evolution in comparison to 3 of 6 (50.0%) with conventional treatment. Patients with complex aberrant karyotypes from the allo-HSCT cohort were more frequently observed with clonal evolution (3 of 4; 75.0%) when compared to the conventionally treated cohort (2 of 9; 22.2%). However, the limited size of the cytogenetic subgroups does not allow any further conclusions.
Complexity of cytogenetic patterns
Cytogenetic patterns were more complex in the allogeneic HSCT patients when compared to the standard cohort both at diagnosis and at relapse of AML (Table 2b and Figure 1A) .
At diagnosis of AML, the HSCT patients had a mean number of 2.0 (standard deviation, SD; 63.0) cytogenetic alterations, the conventionally treated patients had a mean number of 0.9 6 1.5 (P 5 .005). At relapse, those from the allogeneic HSCT cohort were observed with a mean number of 4.0 6 5.4 cytogenetic alterations per patient in comparison to a mean of 1.3 6 2.0 cytogenetic alterations per patient in the conventionally treated cohort (P \ .001). Thus, in the HSCT cohort, the mean difference in the numbers of cytogenetic alterations between diagnosis and relapse per patient was 2.0, whereas in the conventional cohort it was 0.4 (P \ .001).
In more detail, the mean numbers of numeric losses per patient were significantly higher in the HSCT patients when compared to the standard cohort at diagnosis (HSCT: 0.2 6 0.6; conventional: 0.1 6 0.2; P 5 .020) as at relapse (HSCT: 0.3 6 0.7; conventional: 0.1 6 0.3; P 5 .001). Also, HSCT patients had significantly higher mean numbers of structural unbalanced alterations at diagnosis and relapse of AML than the standard cohort (diagnosis: HSCT: mean number, 1.2 6 2.6; conventional: 0.4 6 1.2; P 5 .014; relapse: HSCT: mean, 2.7 6 5.1; conventional: mean: 0.6 6 1.5; P \ .001) ( Figure 1B) .
Regarding the mean numbers of numeric gains and balanced rearrangements, there was no significant difference between the allo-HSCT cohort and the conventionally treated patients at diagnosis and relapse (mean number of numeric gains at diagnosis: HSCT: 0.3 6 0.7; conventional: 0.2 6 0.6; relapse: HSCT: 0.4 6 0.9; conventional: 0.3 6 0.7; balanced rearrangements at diagnosis: HSCT: 0.3 6 0.4; conventional: 0.2 6 0.4; relapse: HSCT: 0.7 6 0.9; conventional: 0.3 6 0.7).
DISCUSSION
Because of the selection of poor risk AML cases for allogeneic HSCT [3] [4] [5] , relapse in the posttransplant period remains a central problem in hematopoietic stem cell transplantation. Several studies focused on the early detection of relapse of AML in the posttransplant period with assessment of minimal residual disease or chimerism analysis [15, 16] , or on therapeutic strategies in this difficult clinical situation [17, 18] . However, not much is known about the specific biology of relapsed AML in the posttransplant period in comparison to relapse after standard chemotherapy of AML. Although previous studies demonstrated that relapse of an acute leukemia was frequently accompanied by the acquisition of new cytogenetic alterations [8, 9] , to our knowledge, so far no study performed comparison of cytogenetic clonal evolution in recipients of allogeneic HSCT versus conventional therapy in patients with AML. Recently, Schmidt-Hieber et al. [10] analyzed the cytogenetic patterns of 22 patients relapsing from AML and ALL after allogeneic HSCT and described changes of karyotypes in 68% of patients from this cohort.
In this study, we compared the patterns of clonal cytogenetic evolution in 160 patients with relapse of AML either after allogeneic HSCT or after conventional chemotherapy. First, alterations of the cytogenetic patterns from the first manifestation of AML to relapse were more frequently seen in the recipients of HSCT with 53.8% of affected cases than in the conventionally treated cohort with 36.6% of cases. These different cytogenetic patterns were most frequently because of the acquisition of new cytogenetic alterations (''clonal evolution'') with a higher frequency in the HSCT cohort when compared to the conventionally treated patients (46.2% veresus 30.6%). Loss of clonal alterations at relapse-corresponding to clonal regression-was rare in both cohorts (HSCT: 11.5%; conventional cohort: 12.7%). When the types of new cytogenetic alterations were characterized in more detail, some striking differences were observed between the cohorts: the transplant patients showed a higher frequency of new complex cytogenetic alterations, meaning the acquisition of at least 3 new clonal cytogenetic alterations, when compared to the conventionally treated cohort (50.0% versus 12.2% of those with the phenomenon of clonal cytogenetic evolution).
We then compared the cytogenetic complexity of the stem cell recipients and those from the conventionally treated cohort. Stem cell recipients had a significantly higher mean number of cytogenetic alterations at relapse of AML when compared to the conventionally treated cohort (4.0 versus 1.3 alterations per patient; P 5 .005) and the difference between the mean number of cytogenetic alterations per patient from diagnosis to relapse was 2.0 in the HSCT cohort but 0.4 only in the standard-treated patients (P \ .001). Further, the HSCT patients showed significantly higher mean numbers of numeric losses and unbalanced structural rearrangements at diagnosis as at relapse when compared to the conventionally treated cohort.
Thus, higher rates of clonal evolution and higher cytogenetic complexity at relapse and at diagnosis were observed in the HSCT patients in our study. These results suggest higher levels of genetic instability at diagnosis, but also at relapse in the allo-transplant cohort, which might be seen in association to the more adverse and complex cytogenetic profiles of patients already at diagnosis of AML: according to the earlier results, the HSCT patients had higher rates of abnormal karyotypes, a higher frequency of unfavorable karyotypes (30.8% versus 14.2%), and higher complexity of karyotypes already at diagnosis of AML when compared to the conventionally treated patients. Second, the higher treatment intensity regarding conditioning regimens in the HSCT patients when compared to those with conventional treatment might play a role.
As data on AML is missing so far, we compared our results to chronic myelogenous leukemia: patients with relapse or persistence of the disease after HSCT were reported to show different cytogenetic patterns when compared to those after autologous HSCT [19, 20] . Karrman et al. [20] reviewed 131 patients with CML with cytogenetic evolution after allogeneic or autologous HSCT. In the recipients of allogeneic HSCT, major route abnormalities were underrepresented with 15% of all cases only when compared to 67% in autologous HSCT (P 5 .07), and balanced translocations were significantly more frequent (66 versus 22%, P 5 .03). There was a trend toward pseudodiploidy after allogeneic HSCT in contrast to a trend toward hyperdiploidy after autologous HSCT. Factors such as BM environment, the presence of donor cells, or immunosuppression were suggested to explain the different cytogenetic evolution patterns in CML patients post allo-HSCT. Thus, it seems that in CML, the differences of the cytogenetic evolution patterns in dependence of the previous treatment strategies might be more pronounced than in AML as we were not able to determine such substantial differences in the types of cytogenetic alterations.
In conclusion, patients who relapse from AML after allogeneic HSCT have a higher frequency of clonal cytogenetic evolution and show higher genetic complexity at relapse when compared to patients who relapse after standard chemotherapy. These results suggest higher genetic instability probably associated to the more unfavorable cytogenetic profiles already at diagnosis of AML when both cohorts are compared, and the more advanced clinical stages of the HSCT patients have to be considered as well. Thus, the cytogenetic characterization of relapse of AML in stem cell recipients helps to explain the adverse prognosis of stem cell recipients at relapse of AML and emphasizes the need for specific and novel treatment approaches for this high risk cohort. Future studies should focus on the clinical impact of cytogenetic patterns in patients with posttransplant relapse of AML. Finally, the inclusion of larger cohorts of HSCT recipients would allow the correlation of the individual stages of AML before transplantation with the frequency and the clonal evolution patterns at posttransplant relapse.
